Get the Stockscreener App
2.80
2.94%
0.08
Pre-market:
2.76
-0.04
-1.43%
Evotec Se Adr stock is traded at $2.80, with a volume of 37,088.
It is up +2.94% in the last 24 hours and up +3.70% over the past month.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
See More
Previous Close:
$2.72
Open:
$2.82
24h Volume:
37,088
Relative Volume:
0.43
Market Cap:
$994.53M
Revenue:
$863.66M
Net Income/Loss:
$-225.27M
P/E Ratio:
-4.415
EPS:
-0.6342
Net Cash Flow:
$-63.28M
1W Performance:
-0.36%
1M Performance:
+3.70%
6M Performance:
-6.04%
1Y Performance:
-34.43%
1-Day Range:
$2.80
$2.83
1-Week Range:
$2.59
$2.83
52-Week Range:
$2.308
$4.415
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
2.80 | 994.53M | 863.66M | -225.27M | -63.28M | -0.6342 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Resumed | H.C. Wainwright | Buy |
| Feb-03-26 | Initiated | Berenberg | Buy |
| Apr-24-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Oct-07-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jul-29-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-11-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Evotec SE Stock (DE0005664809): Short Interest Eases While Shares Trade Near Lows - AD HOC NEWS
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec - news.financial
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Nigeria
Evotec SE stock (DE0005664809): After CEO exit and audit delay, investors watch turnaround plans - AD HOC NEWS
Evotec ADR Slides 4.3% as Selling Pressure Tests Key Support LevelsQuality Factor - The Legal Advocate
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus! - news.financial
Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion - AD HOC NEWS
Evotec AG Earnings Call Balances Pain With Promise - The Globe and Mail
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth - AD HOC NEWS
Evotec places €116.1 million convertible bonds due 2033 - Investing.com UK
Evotec places €116.1 million convertible bonds due 2033 By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum - AD HOC NEWS
Evotec SE stock (DE0005664809): HC Wainwright cuts Q2 earnings outlook - AD HOC NEWS
Boyd Gaming posts downbeat Q1 results, joins Coursera, Evotec and other big stocks moving lower in Friday's pre-market session - MSN
Evotec SE stock (DE0005664809): Q1 2026 results show sharp revenue drop amid restructuring - AD HOC NEWS
Take note! The stock market is (still) ignoring key developments at Desert Gold, Evotec, and Mutares! - news.financial
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates By Investing.com - Investing.com Nigeria
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges By Investing.com - Investing.com South Africa
Evotec reports wider quarterly loss, misses revenue expectations - Investing.com
Evotec's Share Price Surges! Summer Rally for Desert Gold? Rheinmetall Shares Heading Toward EUR 2,000? - news.financial
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today - AD HOC NEWS
Evotec nominates Wolfgang Hofmann to supervisory board By Investing.com - Investing.com Australia
Evotec nominates Wolfgang Hofmann to supervisory board - Investing.com
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin By Investing.com - Investing.com Australia
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday - Benzinga
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin - Investing.com
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough for biotech recovery? - AD HOC NEWS
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):